$4.17
2.71%
Nasdaq, Oct 20, 02:38 pm EDT. Market open.
ISIN
US68403P2039
Symbol
ORMP

Oramed Pharmaceuticals Inc. Stock price

$4.06
-0.64 13.62% 1M
+0.23 6.01% 6M
+1.21 42.46% YTD
+1.77 77.29% 1Y
+1.96 93.33% 3Y
-18.68 82.15% 5Y
-2.79 40.73% 10Y
-4.64 53.33% 20Y
Nasdaq, Closing price Mon, Oct 19 2026
-0.01 0.25%
ISIN
US68403P2039
Symbol
ORMP
Industry

Is Oramed Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.

Key metrics

Basic
Market capitalization
$168.9m
Enterprise Value
$118.3m
Net debt
positive
Cash
$50.6m
Shares outstanding
41.3m
Valuation
P/E
1.0
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
0.5
Financial Health
Equity Ratio
86.5%
Return on Equity
32.1%
ROCE
-4.1%
ROIC
-3.7%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$7.7m | -
SBC as % of FCF
-
SBC Growth 1Y
169.3%
Share Count Growth 1Y
0.8%
Shareholder Yield
-0.8%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-14.4m
EBIT
$-14.5m
Net Income
$174.9m
Free Cash Flow | ex SBC
$-5.2m | $-13.0m
Growth
Revenue | estimate
-100.0% | -100.0%
EBITDA
-6.4%
EBIT
-6.2%
Net Income
823.8%
Free Cash Flow
67.6%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$4.1
FCF per Share
$-0.1
Short interest
4.2%
Employees
4
Rev per Employee
$500.0k

Oramed Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Oramed Pharmaceuticals Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Oramed Pharmaceuticals Inc. forecast:

Hold
50%
Sell
50%

Financial data from Oramed Pharmaceuticals Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.79 9.79
45% 45%
-
- Research and Development Expense 4.74 4.74
32% 32%
-
-14 -14
6% 6%
-
- Depreciation and Amortization 0.12 0.12
14% 14%
-
EBIT (Operating Income) EBIT -15 -15
6% 6%
-
Net Profit 175 175
824% 824%
-

In millions USD.

Don't miss a Thing! We will send you all news about Oramed Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Oramed Pharmaceuticals Inc. Stock News

Neutral
PRNewsWire
●
4 months ago
Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million) Scilex (NASDAQ: SCLX) Loan Substantially Repaid Total Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026) Oramed to Join the Russell 2000 and Russell 3000 Indexes this week NEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals In...
Neutral
PRNewsWire
●
4 months ago
NEW YORK, June 17, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index at the conclusion of the 2026 Russell indexes semi-annual reconstitution. The 2026 Russell 2000 and Russell 3000 reconstitution becomes final after the close of US markets on...

Company Profile

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in Jerusalem, Israel.

Head office United States
CEO Mr. Kidron
Employees 4
Founded 2002
Website oramed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today